Today on Drug Discovery & Development
Bayer to acquire AskBio for up to $4B
FDA approves remdesivir as a COVID-19 treatment
Drug Discovery and Development See More >
Bayer to acquire AskBio for up to $4B
Bayer (FRA: BAYN) announced today that it will acquire gene therapy startup AskBio for an upfront payment of $2 billion. The German life sciences giant could shell out an additional $2 billion if the startup meets specific criteria. Rather than folding AskBio’s operations into its own, Bayer stressed in a statement that the startup would operate independently…
Genomics/Proteomics See More >
The top 10 medical disruptors of 2021
For the past 18 years, the Cleveland Clinic has predicted what the top 10 medical disruptors will be for the following year. The list of technologies, cultivated by a panel of physicians and scientists at the clinic, was led by Dr. Will Morris, executive medical director of Cleveland Clinic Innovations, and Dr. Akhil Saklecha, managing…
Infectious Disease See More >
AstraZeneca: Vaccine candidate prompts immune response in seniors
AstraZeneca (NASDAQ:AZN) announced today that its potential COVID-19 vaccine prompts an immune response in older and younger adults. The vaccine candidate is currently in a Phase 3 trial. In September, the company had put its vaccine trial on hold after a U.K. participant suffered neurological symptoms. But the AZD1222 vaccine candidate appears to be safe based on…
Oncology See More >
The top 10 medical disruptors of 2021
For the past 18 years, the Cleveland Clinic has predicted what the top 10 medical disruptors will be for the following year. The list of technologies, cultivated by a panel of physicians and scientists at the clinic, was led by Dr. Will Morris, executive medical director of Cleveland Clinic Innovations, and Dr. Akhil Saklecha, managing…
